MedTrace Logo

LEAP2 on Postprandial Glucose Metabolism and Food Intake

NCT04621409 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-05-26

No results posted yet for this study

Summary

The study aim to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in healthy volunteers. The overall objective is to investigate the physiological importance of LEAP-2 in healthy subjects.

Conditions

Interventions

BIOLOGICAL

Liver-enriched antimicrobial peptide 2

IV infusion of LEAP2, approximately 5 hours

BIOLOGICAL

Placebo

IV infusion of saline, approximately 5 hours

Sponsors & Collaborators

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Filip K Knop, MD, PhD · Center for Clinical Metabolic Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-17
Primary Completion
2021-02-18
Completion
2021-02-18

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04621409 on ClinicalTrials.gov